Acknowledgements
Cancer
CANCER
The authors would like to acknowledge all trial participants, the National Cancer Institute for trial support and AstraZeneca for supply of olaparib through a cooperative research and development agreement with the National Cancer Institute. The clinical trial protocol was written at the 2016 ASCO-AACR Methods in Clinical Cancer Research Workshop. 